-transparent.png){kind=logo}
Clinical pharmacology of linezolid: an oxazolidinone antimicrobial agent. 2008
Department of Pediatrics, Feinberg School of Medicine, Northwestern University, Division of Infectious Diseases, Children's Memorial Hospital, Chicago, IL 60614-3363, USA. titan@childrensmemorial.org.
The oxazolidinones are a new class of antibiotics whose mechanism of action is the inhibition of bacterial protein synthesis by binding to the 50S ribosomal subunit. Linezolid is the first member of this class of antibiotics to be approved by the US FDA and other regulatory bodies for the treatment of infections caused by antibiotic-resistant Gram-positive pathogens, such as methicillin-resistant Staphylococcus aureus, glycopeptide-intermediate S. aureus and vancomycin-resistant Enterococcus, in adults and children.
| UI | MeSH Term | Description | Entries |
|---|
Related Publications
Tina Q Tan, and
Ram Yogev
March 2001,
Clinical therapeutics,
Tina Q Tan, and
Ram Yogev
December 2002,
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,
Tina Q Tan, and
Ram Yogev
November 2003,
Annals of internal medicine,
Tina Q Tan, and
Ram Yogev
November 2003,
Annals of internal medicine,
Tina Q Tan, and
Ram Yogev
November 2003,
Annals of internal medicine,
Tina Q Tan, and
Ram Yogev
January 2003,
Annals of internal medicine,
Tina Q Tan, and
Ram Yogev
March 2011,
Annals of the New York Academy of Sciences,
Tina Q Tan, and
Ram Yogev
August 2001,
Current drug targets. Infectious disorders,
Tina Q Tan, and
Ram Yogev
January 2003,
Clinical pharmacokinetics,
Tina Q Tan, and
Ram Yogev
September 2005,
Medecine et maladies infectieuses,
